Somatostatin analogues do not prevent carcinoid crisis

Area of Science:

• Oncology
• Endocrinology
• Pharmacology

Background:

• Carcinoid crisis is a severe complication of neuroendocrine tumors (NETs), marked by hemodynamic instability.
• Prophylactic use of somatostatin analogues (SSTA) is recommended before procedures, but its efficacy remains debated.
• Increasingly effective anti-tumor therapies may heighten the risk of carcinoid crisis due to associated patient stress.

Purpose of the Study:

• To review the efficacy of somatostatin analogues (SSTA) in preventing carcinoid crisis.
• To analyze existing literature on SSTA use for perioperative carcinoid crisis prevention in NET patients.

Main Methods:

• A systematic literature search was conducted on PubMed, Cochrane, and EMBASE databases until December 2013.
• Search terms included 'carcinoid crisis' combined with 'somatostatin', 'octreotide', 'lanreotide', and 'pasireotide'.
• A meta-analysis of two case-control studies was performed on fifty-three unique patients from twenty-eight retrieved articles.

Main Results:

• No randomized controlled trials were identified; analysis included retrospective data.
• The most frequent NET primary sites were the small intestine and respiratory tract.
• Prophylactic SSTA administration showed no significant reduction in the overall risk of perioperative carcinoid crisis (OR 0.44, 95% CI: 0.14 to 1.35, p=0.15).

Conclusions:

• Based on meta-analysis of retrospective studies, SSTA did not effectively prevent carcinoid crisis.
• Close patient monitoring and meticulous intervention strategies are essential for managing carcinoid crisis.
• Higher quality studies are required to definitively ascertain the role of SSTA in preventing carcinoid crisis.